AstraZeneca signs CSPC China deal for experimental kidney disease drugs
CSPC is eligible to receive US$30 million as upfront payment and up to US$1.7 billion in additional payments
Add BT as a preferred source
[SHANGHAI] AstraZeneca has entered into a deal, worth up to US$1.8 billion with CSPC Pharmaceutical Group, to discover and develop experimental medicines with the potential to treat kidney diseases, the Chinese drugmaker said on Thursday (Jul 2).
CSPC’s Hong Kong stock exchange filing did not disclose the specific diseases the medicines would target. The World Health Organization said that an estimated 674 million people worldwide have chronic kidney disease, which progresses gradually.
AstraZeneca will have the option to obtain exclusive rights to develop, manufacture and commercialise one preclinical small nucleic acid drug candidate globally, and a second outside China.
CSPC is eligible to receive US$30 million as an upfront payment, and up to about US$1.7 billion in additional payments tied to development and sales-related milestones.
AstraZeneca has previously entered into collaborations with CSPC, including on obesity and weight-related conditions.
AstraZeneca declined to comment on what diseases would be targeted under the new CSPC deal. REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
Taiwan’s wealthy seeks diversification to Singapore, sparking private banking race: Bloomberg
Palm oil stocks set to surge as Indonesia said to be scaling back export overhaul: analysts
Serenity Park condo owners lower asking price to S$440 million in second shot at collective sale
Malaysian tycoon Vincent Tan’s sell-downs point to pruning rather than an exit plan
